非酒精性脂肪性肝病的治疗：2022年更新
Therapies for non-alcoholic fatty liver disease: A 2022 update.
作者信息
Shen Katie, Singh Achintya D, Modaresi Esfeh Jamak, Wakim-Fleming Jamile
机构信息
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.
Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.
出版信息
World J Hepatol. 2022 Sep 27;14(9):1718-1729. doi: 10.4254/wjh.v14.i9.1718.
Abstract
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and lifestyle interventions to treat this disease by addressing the underlying metabolic syndrome are often limited. Many pharmacological interventions are being studied to slow or even reverse NAFLD progression. This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development.
摘要
非酒精性脂肪性肝病（NAFLD）的发病率正在迅速上升，通过解决潜在的代谢综合征来治疗这种疾病的生活方式干预措施往往有限。目前正在研究许多药物干预措施，以减缓甚至逆转NAFLD的进展。这篇面向肝病学家的综述旨在提供对NAFLD发病机制、当前推荐疗法以及目前正在研发的最有前景的治疗选择的最新认识。
相似文献
1
Therapies for non-alcoholic fatty liver disease: A 2022 update.
World J Hepatol. 2022 Sep 27;14(9):1718-1729. doi: 10.4254/wjh.v14.i9.1718.
2
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
3
From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
Proc Nutr Soc. 2019 Aug;78(3):290-304. doi: 10.1017/S0029665119000570. Epub 2019 Mar 29.
4
Management of non-alcoholic fatty liver disease.
Minerva Gastroenterol Dietol. 2013 Mar;59(1):69-87.
5
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Ann Transl Med. 2021 Apr;9(8):729. doi: 10.21037/atm-20-4354.
6
Promising therapies for treatment of nonalcoholic steatohepatitis.
Expert Opin Emerg Drugs. 2016 Sep;21(3):343-57. doi: 10.1080/14728214.2016.1220533. Epub 2016 Aug 28.
7
Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
Eur J Pediatr. 2014 Feb;173(2):131-9. doi: 10.1007/s00431-013-2157-6. Epub 2013 Sep 26.
8
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
9
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.
Front Pharmacol. 2020 Dec 3;11:603926. doi: 10.3389/fphar.2020.603926. eCollection 2020.
10
The epidemiology of non-alcoholic fatty liver disease.
Liver Int. 2017 Jan;37 Suppl 1:81-84. doi: 10.1111/liv.13299.
引用本文的文献
1
Impact of Pathological Grades of Metabolic Dysfunction-Associated Steatotic Liver Disease on Weight Loss Following Laparoscopic Sleeve Gastrectomy.
Diabetes Metab Syndr Obes. 2025 Jul 29;18:2547-2560. doi: 10.2147/DMSO.S523771. eCollection 2025.
2
Diagnostic value of serologic biomarkers for the detection of liver fibrosis in non-alcoholic fatty liver disease.
Caspian J Intern Med. 2025 Mar 11;16(2):275-283. doi: 10.22088/cjim.16.2.275. eCollection 2025.
3
Exploratory analysis of the association between dietary niacin intakes and nonalcoholic fatty liver disease among US adults: 1999-2018 data analysis from the National Health and Nutrition Examination Survey (NHANES).
J Clin Biochem Nutr. 2025 Mar;76(2):179-186. doi: 10.3164/jcbn.23-63. Epub 2024 Jan 16.
4
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.
Medicine (Baltimore). 2024 Nov 1;103(44):e40364. doi: 10.1097/MD.0000000000040364.
5
Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical Trial.
Gastro Hep Adv. 2023 Dec 7;3(3):417-425. doi: 10.1016/j.gastha.2023.11.016. eCollection 2024.
6
Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-Analysis.
J Pers Med. 2024 Mar 2;14(3):281. doi: 10.3390/jpm14030281.
7
Molecular Drug Simulation and Experimental Validation of the CD36 Receptor Competitively Binding to Long-Chain Fatty Acids by 7-Ketocholesteryl-9-carboxynonanoate.
ACS Omega. 2023 Jul 28;8(31):28277-28289. doi: 10.1021/acsomega.3c02082. eCollection 2023 Aug 8.
8
Research progress on the therapeutic effects of polysaccharides on non-alcoholic fatty liver diseases.
Front Nutr. 2023 Mar 10;10:1107551. doi: 10.3389/fnut.2023.1107551. eCollection 2023.
本文引用的文献
1
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16.
2
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Nat Med. 2021 Jul;27(7):1262-1271. doi: 10.1038/s41591-021-01425-3. Epub 2021 Jul 8.
3
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.
J Biol Chem. 2021 Jan-Jun;296:100807. doi: 10.1016/j.jbc.2021.100807. Epub 2021 May 20.
4
Non-alcoholic fatty liver disease.
Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21.
5
An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents.
J Clin Transl Hepatol. 2021 Feb 28;9(1):60-70. doi: 10.14218/JCTH.2020.00040. Epub 2021 Jan 4.
6
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Gastroenterology. 2021 Feb;160(3):912-918. doi: 10.1053/j.gastro.2020.11.051. Epub 2020 Dec 9.
7
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
8
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
Gut. 2021 Mar;70(3):522-530. doi: 10.1136/gutjnl-2020-322753. Epub 2020 Nov 9.
9
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39. doi: 10.1038/s41575-020-00366-5. Epub 2020 Oct 22.
10
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.
Contemp Clin Trials. 2020 Nov;98:106170. doi: 10.1016/j.cct.2020.106170. Epub 2020 Oct 8.
Zotero 插件